3',4'-Methylenedioxy-α-pyrrolidinopropiophenone

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone
Clinical data
Routes of
administration		 oral, insufflation, Vaporization, IV, rectal, sublingual
Legal status
Legal status
Pharmacokinetic data
Metabolism Hepatic
Excretion Primarily Urine (Renal)
Identifiers
CAS Number
PubChem CID
ChemSpider
ECHA InfoCard 100.230.213 Edit this at Wikidata
Chemical and physical data
Formula C14H17NO3
Molar mass 247.28 g/mol
3D model (JSmol)
Chirality Racemic mixture

3',4'-Methylenedioxy-α-pyrrolidinopropiophenone (MDPPP) is a stimulant designer drug. It was sold in Germany in the late 1990s and early 2000s as an ingredient in imitation ecstasy (MDMA) pills.[1] It shares a similar chemical structure with α-PPP and MDPV,[2][3][4] and has been shown to have reinforcing effects in rats.[5]

Metabolism

MDPPP appears to have a similar metabolic fate as MDPV.[4]

As of October 2015 MDPPP is a controlled substance in China.[6]

See also

References

  1. ↑ Springer, D.; Fritschi, G.; Maurer, H. H. (2003). "Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy-α-pyrrolidinopropiophenone studied in urine using gas chromatography–mass spectrometry". Journal of Chromatography B. 793 (2): 377. doi:10.1016/S1570-0232(03)00350-7.
  2. ↑ Maurer, HH; Kraemer, T; Springer, D; Staack, RF (2004). "Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis". Therapeutic drug monitoring. 26 (2): 127–31. doi:10.1097/00007691-200404000-00007. PMID 15228152.
  3. ↑ Staack, RF; Maurer, HH (2005). "Metabolism of designer drugs of abuse". Current Drug Metabolism. 6 (3): 259–74. doi:10.2174/1389200054021825. PMID 15975043.
  4. 1 2 Springer, D; Staack, RF; Paul, LD; Kraemer, T; Maurer, HH (2005). "Identification of cytochrome P450 enzymes involved in the metabolism of 3',4'-methylenedioxy-alpha-pyrrolidinopropiophenone (MDPPP), a designer drug, in human liver microsomes". Xenobiotica. 35 (3): 227–37. doi:10.1080/00498250400028239. PMID 16019948.
  5. ↑ Gannon, BM; Galindo, KI; Mesmin, MP; Sulima, A; Rice, KC; Collins, GT (12 August 2017). "Relative reinforcing effects of second-generation synthetic cathinones: Acquisition of self-administration and fixed ratio dose-response curves in rats". Neuropharmacology. doi:10.1016/j.neuropharm.2017.08.018. PMID 28811192.
  6. ↑ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.